Tags : CHMP’s

Biotech

Novartis’ Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP’s Expanded

Shots: The combination therapy recommendation of Kisqali plus endocrine therapy is based on results of P-III MONALEESA-7 and MONALEESA-3 trials assessing Kisqali vs endocrine therapy alone in women with HR+/HER2- Locally Advanced or Metastatic Breast Cancer P-III MONALEESA-7 and MONALEESA-3 study results: mPFS (27.5 mos., 20.5 mos. vs 13.8 mos., 12.8 mos.) as 1L or […]Read More